Genovis AB (publ.) (STO:GENO)

Market Cap	1.27B
Revenue (ttm)	146.00M
Net Income (ttm)	32.92M
Shares Out	65.47M
EPS (ttm)	0.50
PE Ratio	38.58
Forward PE	43.11
Dividend	n/a
Ex-Dividend Date	n/a

Volume	54,240
Average Volume	147,724
Open	20.00
Previous Close	19.40
Day's Range	19.22 - 21.00
52-Week Range	17.10 - 39.85
Beta	1.92
RSI	44.38
Earnings Date	Apr 28, 2025

About Genovis AB (publ.)

Genovis AB (publ.) develops and sells tools for the development of new treatment methods and diagnostics for customers in the pharmaceutical and research industries. The company provides FabALACTICA, a cysteine protease; FabRICATOR, a cysteine protease; and FabRICATOR Z, for the digestion of mouse IgG2a and IgG3, and generating a homogenous pool of F(ab')2 and Fc fragments. It offers FabULOUS (SpeB), a cysteine protease; GingisKHAN, a cysteine protease; FabDELLO, a protease that digests human IgG1; IgASAP, an IgA-digesting enzyme; and IgMBRAZOR...

• Industry: Biotechnology
• Sector: Healthcare
• Founded: 1999
• Employees: 32
• Stock Exchange: Nasdaq Stockholm
• Ticker Symbol: GENO

Financial Performance

In 2024, Genovis AB (publ.)'s revenue was 146.00 million, a decrease of -8.22% compared to the previous year's 159.07 million. Earnings were 32.92 million, a decrease of -46.48%.